Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOKYO.L Regulatory News (OKYO)

  • There is currently no data for OKYO

Disposal

9 Jul 2010 11:44

For Immediate Release: 9 July 2010

EMERGING METALS LIMITED ("EML" or the "Company") Disposal

The Company is pleased to announce that it has entered into an agreement to dispose of its entire holding of 368,721 shares in Extract Resources Limited ("EXT Shares") to Nippon Uranium Resources (Australia) Proprietary Limited at a price of A$7.00 in cash per EXT Share. The gross proceeds of the sale will be A$2,581,047, approximately £1.48 million, which will be available for EML to apply in accordance with its investing policy approved by shareholders on 16 April. The sale is conditional on certain Australian regulatory approvals and completion is expected to be no later than 17 August 2010.

Extract Resources Limited ("EXT") is an ASX listed uranium exploration and development company with significant uranium assets in Namibia, namely the Husab uranium project comprising the Rossing South, Ida Dome and Hildenhof deposits and the EXT Shares represent approximately 0.15 per cent. of EXT's issued share capital.

ENQUIRIES:Emerging Metals Religare Capital Fox-Davies Capital GTH Communications Limited Markets Limited Daniel Fox-Davies Denham Eke Peter Toby Hall Trevelyan-Clark +44 (0) 20 7936 +44 (0) 1624 5200 Christian Pickel 639396 Emily Staples +44 (0) 20 3103 3900 +44 (0) 20 7444 0800

vendor
Date   Source Headline
19th Mar 20207:00 amRNSPlacing to raise £560,000
2nd Mar 202011:50 amRNSResult of AGM
19th Dec 20197:00 amRNSDirectorate Change
29th Nov 20197:00 amRNSHalf-year Report
28th Aug 20197:00 amRNSChemerin Update
19th Aug 20197:00 amRNSCollaboration with Prof. Pedram Hamrah
30th Jul 20192:05 pmRNSSecond Price Monitoring Extn
30th Jul 20192:00 pmRNSPrice Monitoring Extension
1st Jul 20197:00 amRNSFinal Results
30th May 20192:52 pmRNSHolding(s) in Company
20th May 201910:58 amRNSResult of General Meeting
26th Apr 20197:00 amRNSSubscription and Waiver
25th Apr 20195:30 pmRNSHolding(s) in Company
7th Mar 20197:00 amRNSPresentation of Preclinical Data
23rd Jan 20197:00 amRNSCorporate Update
30th Nov 20184:06 pmRNSHalf-year Report
1st Nov 20187:00 amRNSExpected Admission Date for Consideration Shares
24th Oct 20187:00 amRNSAllotment of Ordinary Shares & Listing Application
21st Sep 20187:00 amRNSAppointment of Senior R&D Director
6th Sep 201812:38 pmRNSResult of AGM
22nd Aug 201812:13 pmRNSHolding(s) in Company
21st Aug 201812:09 pmRNSAnnual Report and Notice of AGM
31st Jul 20186:05 pmRNSFinal Results
9th Mar 201811:01 amRNSResult of General Meeting and Corporate Update
2nd Mar 201812:47 pmRNSChange of Broker
21st Feb 20185:00 pmRNSProposed cancellation, suspension, notice of GM
21st Feb 20185:00 pmRNSSuspension - Okyo Pharma Corporation
2nd Feb 20181:17 pmRNSChange of Name and Corporate Update
10th Jan 201811:14 amRNSResult of General Meeting
4th Jan 20189:52 amRNSIssue of Equity, Directors' Dealing
21st Dec 201710:40 amRNSProposed Disposal, Special Dividend, Notice of GM
18th Dec 201712:23 pmRNSInterim Report for Period Ended 30 September 2017
13th Nov 20174:12 pmRNSBoard Changes and Corporate Update
29th Sep 20177:00 amRNSReport and Accounts for year to 31 March 2017
6th Jul 20171:47 pmRNSBoard Appointment
16th Jun 20171:18 pmRNSHolding(s) in Company
8th Jun 20175:07 pmRNSHolding(s) in Company
5th Jun 20177:00 amRNSDirectorate Change
12th May 20177:00 amRNSScoping Study
22nd Dec 201612:34 pmRNSHalf-year Report
29th Sep 20165:50 pmRNSAnnual Financial Report
12th Aug 20167:00 amRNSChange of Broker
1st Apr 201612:44 pmRNSBoard Changes and Corporate Update
11th Feb 20167:00 amRNSDirector's Dealing
22nd Dec 20157:00 amRNSHalf Yearly Report
29th Sep 20153:45 pmRNSAnnual Financial Report
21st Aug 20154:37 pmRNSCorporate Update
27th Jul 20157:00 amRNSDirectors' dealing
2nd Jun 20157:00 amRNSBoard changes and withdrawal of requisition
29th Apr 201512:15 pmRNSRequisition of General Meeting - Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.